These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8091350)

  • 1. [Pharmacokinetics of calcium antagonists].
    Richard MO
    Therapie; 1993; 48 Spec No():651-7. PubMed ID: 8091350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists].
    Rameis H
    Wien Med Wochenschr; 1993; 143(19-20):490-500. PubMed ID: 8135031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
    Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
    Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The kinetic profiles of amlodipine and of a sustained release form of diltiazem.
    Fourtillan JB; Ingrand I; Decourt JP; Istin B; Girault J
    Therapie; 1998; 53(2):121-6. PubMed ID: 9773111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical pharmacology of calcium inhibitors].
    Singlas E; Martre H; Taburet AM
    Arch Mal Coeur Vaiss; 1985 Nov; 78 Spec No():15-22. PubMed ID: 3937500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics and pharmacodynamics of calcium channel blockers].
    Mayer O
    Vnitr Lek; 1995 Mar; 41(3):164-6. PubMed ID: 7762170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of calcium channel antagonists.
    McAllister RG
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S340-5. PubMed ID: 6184565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amlodipine: a new calcium antagonist.
    Clavijo GA; de Clavijo IV; Weart CW
    Am J Hosp Pharm; 1994 Jan; 51(1):59-68. PubMed ID: 8135260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist.
    Abernethy DR
    J Cardiovasc Pharmacol; 1991; 17 Suppl 1():S4-7. PubMed ID: 16296697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension.
    Hilleman DE; Mohiuddin SM; Lucas BD; Shinn B; Elsasser GN
    Clin Ther; 1993; 15(6):1002-10. PubMed ID: 8111798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses.
    Schwarzwald CC; Sams RA; Bonagura JD
    J Vet Pharmacol Ther; 2006 Jun; 29(3):165-71. PubMed ID: 16669860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of diltiazem bioavailability from 3 marketed extended-release products for once-daily administration: implications of chronopharmacokinetics and dynamics.
    Eradiri O; Midha KK
    Int J Clin Pharmacol Ther; 1997 Sep; 35(9):369-73. PubMed ID: 9314089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences between calcium antagonists: duration of action and trough to peak ratio.
    Meredith PA; Reid JL
    J Hypertens Suppl; 1993 Mar; 11(1):S21-6. PubMed ID: 8483017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics and dynamics of Ca-antagonists in relation to the development of their slow release formulas].
    Echizen H; Ishizaki T
    Nihon Rinsho; 1989 Aug; 47(8):1781-7. PubMed ID: 2585741
    [No Abstract]   [Full Text] [Related]  

  • 15. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
    Petrie JR; Glen SK; MacMahon M; Crome R; Meredith PA; Elliott HL; Reid JL
    J Hypertens; 1995 Dec; 13(12 Pt 2):1842-6. PubMed ID: 8903664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of calcium antagonists. An update.
    Kelly JG; O'Malley K
    Clin Pharmacokinet; 1992 Jun; 22(6):416-33. PubMed ID: 1587055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intervessel (arteries and veins) and heart/vessel selectivities of therapeutically used calcium entry blockers: variable, vessel-dependent indexes.
    Magnon M; Gallix P; Cavero I
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1157-66. PubMed ID: 8531077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring.
    Leenen FH; Wilson TW; Bolli P; Larochelle P; Myers M; Handa SP; Boileau G; Tanner J
    Can J Cardiol; 1997 Oct; 13(10):914-20. PubMed ID: 9374947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of calcium antagonists under development.
    Abernethy DR; Schwartz JB
    Clin Pharmacokinet; 1988 Jul; 15(1):1-14. PubMed ID: 3042243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of calcium antagonists.
    Reid JL; Meredith PA; Donnelly R; Elliott HL
    J Cardiovasc Pharmacol; 1988; 12 Suppl 7():S22-6. PubMed ID: 2467122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.